PTSM: Pharmaceutical Technology Sourcing and Management
The company has completed a small-scale capacity expansion at its site in Charles City, IA.
On Nov. 8, 2017, Cambrex announced the completion of a small-scale capacity expansion at its Charles City, IA, site. The expansion includes the installation of two 500-gallon glass-lined reactors and a third small-scale work center.
“Small-scale manufacturing has been identified as being a crucial area where capacity is at a premium within the industry, and this investment has been undertaken to increase our flexibility and reduce potential project bottle necks to benefit our customers,” said Joe Nettleton, vice president of US operations at Cambrex, in a company press release.
This investment comes after the installation of a new pilot plant at the site in 2017 and recent announcements of expansions across other manufacturing sites, including the construction of a $24-million, 4500-ft2 highly potent active pharmaceutical ingredient manufacturing facility at the Charles City site, which is due to open in 2019.
Source: Cambrex
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.